Mesa Laboratories (NASDAQ:MLAB) Director R Tony Tripeny Acquires 900 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director R Tony Tripeny acquired 900 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was purchased at an average price of $113.69 per share, with a total value of $102,321.00. Following the transaction, the director owned 6,298 shares of the company’s stock, valued at approximately $716,019.62. This trade represents a 16.67% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Mesa Laboratories Price Performance

NASDAQ:MLAB opened at $107.64 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. Mesa Laboratories, Inc. has a 52 week low of $58.83 and a 52 week high of $115.52. The stock’s 50-day moving average price is $100.62 and its 200-day moving average price is $96.26. The stock has a market capitalization of $602.78 million, a PE ratio of 128.14 and a beta of 0.92.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The company had revenue of $60.14 million during the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio is 76.19%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after purchasing an additional 143 shares during the last quarter. American Century Companies Inc. grew its holdings in Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after buying an additional 194 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Mesa Laboratories by 30.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after acquiring an additional 243 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Mesa Laboratories by 5.9% in the 4th quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock worth $349,000 after acquiring an additional 248 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 322 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on MLAB. Weiss Ratings upgraded Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Wall Street Zen cut Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Wells Fargo & Company raised their target price on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research report on Friday. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Mesa Laboratories has a consensus rating of “Hold” and a consensus target price of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.